Kalohexis Adds Horizon Therapeutics Veteran to Board Amid Pipeline Push
Event summary
- Kalohexis appoints Jeffrey Sherman, MD, former CMO of Horizon Therapeutics, to its Board of Directors on August 11, 2026.
- Dr. Sherman brings over 35 years of R&D and regulatory expertise from roles at Horizon, IDM Pharma, Takeda, NeoPharm, Searle/Pharmacia, and Squibb/Bristol-Myers Squibb.
- Kalohexis is a clinical-stage biotech focusing on metabolic diseases via the melanocortin system, with lead programs 710GO for obesity and mifomelatide for cancer cachexia.
The big picture
Kalohexis' appointment of Dr. Sherman underscores a strategic focus on leveraging deep regulatory and clinical development expertise to advance its novel metabolic disease pipeline. The move comes amid heightened competition in obesity treatments and cachexia management, where the melanocortin system represents an underexplored therapeutic axis. With Dr. Sherman's background in rare diseases and global clinical strategy, Kalohexis may be positioning itself for more aggressive pipeline expansion or high-value partnerships.
What we're watching
- Pipeline Progression
- How Dr. Sherman's regulatory expertise will accelerate Kalohexis' clinical trials for 710GO and mifomelatide.
- Strategic Governance
- Whether the addition of a seasoned biotech executive signals preparatory moves for future partnerships or acquisitions.
- Market Differentiation
- The pace at which Kalohexis can establish its melanocortin-based therapies as distinct from competitors in obesity and cachexia markets.
Related topics